Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Pioglitazone in NASH
NCT05254626Phase 2Completed
- Sponsor
- Cairo University
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Cairo University. Primary endpoint: Histological Features (Liver Biopsy) at 24 weeks. Started Aug 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05254626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254626.